Ronald M. Bukowski,
Robert A. Figlin,
Robert J. Motzer
Springer New York
3e druk, 2014
9781493916214
Renal Cell Carcinoma
Molecular Targets and Clinical Applications
Specificaties
Gebonden, 613 blz.
|
Engels
Springer New York |
3e druk, 2014
ISBN13: 9781493916214
Rubricering
Verwachte levertijd ongeveer 9 werkdagen
Samenvatting
The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors.
Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.
Specificaties
ISBN13:9781493916214
Taal:Engels
Bindwijze:gebonden
Aantal pagina's:613
Uitgever:Springer New York
Druk:3
Inhoudsopgave
<p>Ch. 1: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years; Ch. 2: RCC: Pathologic and Molecular assessment of Targets; Ch. 3: Targeted Therapy for Metastatic Renal Cell Carcinoma : the First Ten Years; Ch. 4: VHL and HIF in clear cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications; Ch. 5: PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex; Ch. 6: Sporadic RCC – Abnormalities in Histone Modifying Genes; 7: Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?; Ch. 8: First-Generation Tyrosine Kinase Inhibitors – Clinical Results; 9: Second Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status; Ch. 10: Third Generation TKIs (Axitinib, Tivozanib) in RCC: enhanced efficacy and diminished toxicity?; Ch. 11: Anti-VEGF and VEGFR monoclonal antibodies in RCC; Ch. 12: PI3-Kinase, Akt, and mTOR Inhibitors in RCC; Ch. 13: Carbonic anhydrase IX & Monoclonal Antibody G250: relevance as a clinical and biologic target in Renal Cell Carcinoma; Ch. 14: EGFR and HER2: Relevance in Renal Cell Carcinoma; Ch. 15: The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma; Ch. 16: Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance; Ch. 17: Development of Combination Therapy with Targeted Agents; Ch. 18: Side Effects ofTargeted Thearpy; Ch. 19: The Role of Targeted Therapy in Special Populations; Ch. 20: Immunotherapy: the Current Role of Cytokines; Ch. 21: Immune Checkpoint Inhibitors (anti-CTLA4, anti PD-1) in RCC; Ch. 22: Vaccines in RCC: Clinical and Biological Relevance; Ch. 23: Development and Incorporation of Biomarkers in RCC Therapeutics; Ch. 24: Molecularly Targeted Staging Strategies in Renal Cell Carcinoma; Ch. 25: Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma; Ch. 26: The Role of Advocacy in Renal Cell Carcinoma</p>